UBS analyst Michael Leuchten raised the firm’s price target on AstraZeneca to 11,900 GBp from 10,100 GBp and keeps a Neutral rating on the shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca, Merck present final results from Phase III PROpel trial
- Merck, AstraZeneca present final results from Phase 3 PROpel trial
- Compugen: Rilvegostomig expected to progress into Phase 3 this year
- Sophia expands deal with AstraZeneca to include MM approaches to oncology
- AstraZeneca Gains after Q4 Results Beat Estimates
